Oncotarget

Research Papers:

Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types

Laetitia E. Lamberts, Derk Jan A. de Groot, Rico D. Bense, Elisabeth G.E. de Vries and Rudolf S.N. Fehrmann _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:28164-28172. https://doi.org/10.18632/oncotarget.4461

Metrics: PDF 962 views  |   HTML 1259 views  |   ?  


Abstract

Laetitia E. Lamberts1,*, Derk Jan A. de Groot1,*, Rico D. Bense1, Elisabeth G.E. de Vries1, Rudolf S.N. Fehrmann1

1University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, The Netherlands

*These authors have contributed equally to this work

Correspondence to:

Rudolf S.N. Fehrmann, e-mail: r.s.n.fehrmann@umcg.nl

Keywords: mesothelin, drug target, functional genomic mRNA profiling, overexpression, antibody-drug conjugate

Received: March 20, 2015     Accepted: June 19, 2015     Published: July 01, 2015

ABSTRACT

The membrane bound glycoprotein mesothelin (MSLN) is a highly specific tumor marker, which is currently exploited as target for drugs. There are only limited data available on MSLN expression by human tumors. Therefore we determined overexpression of MSLN across different tumor types with Functional Genomic mRNA (FGM) profiling of a large cancer database. Results were compared with data in articles reporting immunohistochemical (IHC) MSLN tumor expression. FGM profiling is a technique that allows prediction of biologically relevant overexpression of proteins from a robust data set of mRNA microarrays. This technique was used in a database comprising 19,746 tumors to identify for 41 tumor types the percentage of samples with an overexpression of MSLN compared to a normal background. A literature search was performed to compare the FGM profiling data with studies reporting IHC MSLN tumor expression. FGM profiling showed MSLN overexpression in gastrointestinal (12–36%) and gynecological tumors (20–66%), non-small cell lung cancer (21%) and synovial sarcomas (30%). The overexpression found in thyroid cancers (5%) and renal cell cancers (10%) was not yet reported with IHC analyses. We observed that MSLN amplification rate within esophageal cancer depends on the histotype (31% for adenocarcinomas versus 3% for squamous-cell carcinomas). Subset analysis in breast cancer showed MSLN amplification rates of 28% in triple-negative breast cancer (TNBC) and 33% in basal-like breast cancer. Further subtype analysis of TNBCs showed the highest amplification rate (42%) in the basal-like 1 subtype and the lowest amplification rate (9%) in the luminal androgen receptor subtype.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4461